Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 394

1.

High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.

He T, Surdez D, Rantala JK, Haapa-Paananen S, Ban J, Kauer M, Tomazou E, Fey V, Alonso J, Kovar H, Delattre O, Iljin K.

Gene. 2017 Jan 5;596:137-146. doi: 10.1016/j.gene.2016.10.021. Epub 2016 Oct 17.

PMID:
27760381
2.

MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor.

Franzetti GA, Laud-Duval K, Bellanger D, Stern MH, Sastre-Garau X, Delattre O.

Oncogene. 2013 Aug 15;32(33):3915-21.

PMID:
22986530
3.

FOXM1 is an oncogenic mediator in Ewing Sarcoma.

Christensen L, Joo J, Lee S, Wai D, Triche TJ, May WA.

PLoS One. 2013;8(1):e54556. doi: 10.1371/journal.pone.0054556. Epub 2013 Jan 24.

4.

Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue.

Gierisch ME, Pfistner F, Lopez-Garcia LA, Harder L, Schäfer BW, Niggli FK.

J Biol Chem. 2016 Dec 23;291(52):26922-26933. doi: 10.1074/jbc.M116.752063. Epub 2016 Nov 8.

5.

PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.

Giorgi C, Boro A, Rechfeld F, Lopez-Garcia LA, Gierisch ME, Schäfer BW, Niggli FK.

Oncotarget. 2015 Oct 6;6(30):28895-910. doi: 10.18632/oncotarget.5000.

6.

Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.

Hensel T, Giorgi C, Schmidt O, Calzada-Wack J, Neff F, Buch T, Niggli FK, Schäfer BW, Burdach S, Richter GH.

Oncotarget. 2016 Jan 12;7(2):1451-63. doi: 10.18632/oncotarget.6385.

7.

Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma.

Boro A, Prêtre K, Rechfeld F, Thalhammer V, Oesch S, Wachtel M, Schäfer BW, Niggli FK.

Int J Cancer. 2012 Nov 1;131(9):2153-64. doi: 10.1002/ijc.27472. Epub 2012 Mar 29.

8.

Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma.

Niedan S, Kauer M, Aryee DN, Kofler R, Schwentner R, Meier A, Pötschger U, Kontny U, Kovar H.

Oncogene. 2014 Jul 24;33(30):3927-38. doi: 10.1038/onc.2013.361. Epub 2013 Sep 2.

9.

FOXO1 is a direct target of EWS-Fli1 oncogenic fusion protein in Ewing's sarcoma cells.

Yang L, Hu HM, Zielinska-Kwiatkowska A, Chansky HA.

Biochem Biophys Res Commun. 2010 Nov 5;402(1):129-34. doi: 10.1016/j.bbrc.2010.09.129. Epub 2010 Oct 8.

10.

BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.

Loganathan SN, Tang N, Fleming JT, Ma Y, Guo Y, Borinstein SC, Chiang C, Wang J.

Oncotarget. 2016 Jul 12;7(28):43504-43517. doi: 10.18632/oncotarget.9762.

11.

Ewing sarcoma EWS protein regulates midzone formation by recruiting Aurora B kinase to the midzone.

Park H, Turkalo TK, Nelson K, Folmsbee SS, Robb C, Roper B, Azuma M.

Cell Cycle. 2014;13(15):2391-9. doi: 10.4161/cc.29337.

12.

Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis.

Stoll G, Surdez D, Tirode F, Laud K, Barillot E, Zinovyev A, Delattre O.

Nucleic Acids Res. 2013 Oct;41(19):8853-71. doi: 10.1093/nar/gkt678. Epub 2013 Aug 8.

13.

Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma.

Sankar S, Bell R, Stephens B, Zhuo R, Sharma S, Bearss DJ, Lessnick SL.

Oncogene. 2013 Oct 17;32(42):5089-100. doi: 10.1038/onc.2012.525. Epub 2012 Nov 26. Erratum in: Oncogene. 2016 Nov 24;35(47):6155-6156.

14.

A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs.

McKinsey EL, Parrish JK, Irwin AE, Niemeyer BF, Kern HB, Birks DK, Jedlicka P.

Oncogene. 2011 Dec 8;30(49):4910-20. doi: 10.1038/onc.2011.197. Epub 2011 Jun 6.

15.

Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.

Grohar PJ, Woldemichael GM, Griffin LB, Mendoza A, Chen QR, Yeung C, Currier DG, Davis S, Khanna C, Khan J, McMahon JB, Helman LJ.

J Natl Cancer Inst. 2011 Jun 22;103(12):962-78. doi: 10.1093/jnci/djr156. Epub 2011 Jun 8.

16.

Functional Genomic Screening Reveals Splicing of the EWS-FLI1 Fusion Transcript as a Vulnerability in Ewing Sarcoma.

Grohar PJ, Kim S, Rangel Rivera GO, Sen N, Haddock S, Harlow ML, Maloney NK, Zhu J, O'Neill M, Jones TL, Huppi K, Grandin M, Gehlhaus K, Klumpp-Thomas CA, Buehler E, Helman LJ, Martin SE, Caplen NJ.

Cell Rep. 2016 Jan 26;14(3):598-610. doi: 10.1016/j.celrep.2015.12.063. Epub 2016 Jan 14.

17.

EWS-FLI1 employs an E2F switch to drive target gene expression.

Schwentner R, Papamarkou T, Kauer MO, Stathopoulos V, Yang F, Bilke S, Meltzer PS, Girolami M, Kovar H.

Nucleic Acids Res. 2015 Mar 11;43(5):2780-9. doi: 10.1093/nar/gkv123. Epub 2015 Feb 20.

18.

Junction region of EWS-FLI1 fusion protein has a dominant negative effect in Ewing's sarcoma in vitro.

Jully B, Vijayalakshmi R, Gopal G, Sabitha K, Rajkumar T.

BMC Cancer. 2012 Nov 12;12:513. doi: 10.1186/1471-2407-12-513.

19.

EWS/FLI is a Master Regulator of Metabolic Reprogramming in Ewing Sarcoma.

Tanner JM, Bensard C, Wei P, Krah NM, Schell JC, Gardiner J, Schiffman J, Lessnick SL, Rutter J.

Mol Cancer Res. 2017 Nov;15(11):1517-1530. doi: 10.1158/1541-7786.MCR-17-0182. Epub 2017 Jul 18.

PMID:
28720588
20.

Long noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis.

Marques Howarth M, Simpson D, Ngok SP, Nieves B, Chen R, Siprashvili Z, Vaka D, Breese MR, Crompton BD, Alexe G, Hawkins DS, Jacobson D, Brunner AL, West R, Mora J, Stegmaier K, Khavari P, Sweet-Cordero EA.

J Clin Invest. 2014 Dec;124(12):5275-90. doi: 10.1172/JCI72124. Epub 2014 Nov 17.

Supplemental Content

Support Center